Skip to main content

Table 1 Baseline characteristics of study participants (n = 10)

From: HIV treatment simplification to elvitegravir/cobicistat/emtricitabine/tenofovir disproxil fumarate (E/C/F/TDF) plus darunavir: a pharmacokinetic study

Subject no. Gender Age, years Weight, kg eGFR, mL/min Viral load, copies/mL CD4, cells/mm3 Antiretroviral regimen (with tenofovir DF and emtricitabine)
1 Male 59 92.5 78 < 40 180 RAL 400 mg twice daily
DRV 800 mg daily
Ritonavir 100 mg daily
2 Male 47 89.5 60 < 40 510 RAL 400 mg twice daily
DRV 800 mg daily
Ritonavir 100 mg daily
3 Male 71 63 62 < 40 400 RAL 400 mg twice daily
ATV 300 mg daily
Ritonavir 100 mg daily
4 Male 55 101.5 85 < 40 900 RAL 400 mg twice daily
DRV 800 mg daily
Ritonavir 100 mg daily
5 Female 42 56 84 < 40 900 RAL 400 mg twice daily
DRV 600 mg twice daily
Ritonavir 100 mg twice daily
6 Male 33 85.5 102 < 40 410 RAL 400 mg twice daily
ATV 300 mg daily
Ritonavir 100 mg daily
7 Male 53 72 95 < 40 500 RAL 400 mg twice daily
DRV 800 mg daily
Ritonavir 100 mg daily
8 Male 56 95.5 74 < 40 700 DTG 50 mg daily
DRV 800 mg daily
Ritonavir 100 mg daily
9 Female 48 84 100 < 40 50 RAL 400 mg twice daily
DRV 800 mg daily
Ritonavir 100 mg daily
10 Male 47 98.5 75 134 1020 RAL 400 mg twice daily
ATV 300 mg daily
Ritonavir 100 mg daily
  1. eGFR estimated glomerular filtration rate, RAL raltegravir, DTG dolutegravir, DRV darunavir, ATV atazanavir